Discussing the interaction between polatuzumab & cell of origin subtype in DLBCL in research to practice lymphoma session #ASH23 Table below of COO across 7 studies We explain biological rationale & why this is no ordinary subgroup analysis ⬇️ https://t.co/FGjQP8IIJr #lymsm

everyone talks about San Francisco, but why no one talks about this

SCI member @AshAlizadeh & others provide the first direct evidence for the presence of genetic alterations in circulating precursor cells years before overt #FollicularLymphoma development, dominated by CREBBP mutations within the KAT domain. https://t.co/dHkXrUJKIQ #lymsm

We had a lovely interview with @schroersmartin at #17ICML, who shared some insights into the use of patient-derived organoids to investigate T-cell engager immunotherapy in FL. Watch here: 🎥 https://t.co/uznMmSzJKj @icmlugano #LymSM #HemOnc

A fantastic thread from the person who I think knows more about elderly Hodgkin than anyone else in the world! #lymsm

U) Also great to see data at #17ICML on biologic differences in older HL pts. There has been a paucity of data on this topic to date.

Jan Bögeholz & Cedric Rossi @icmlugano #17icml

@schroersmartin Packed room at the TME session and tons of questions for @schroersmartin about his awesome talk!

Abstract presentation this evening in the Focus on TME session #17ICML @AshAlizadeh @lisa_wagar @Jkastens_phd @max_diehn

Distinct molecular determinants of treatment-failure in elderly Hodgkin lymphoma identified by cell-free DNA profiling: A LYSA Study #PhasEDSeq @LysaLymphoma Cedric Rossi @StefanAlig @schroersmartin @mohamshah @max_diehn @TakeshiSugio @nonoscherlebeck https://t.co/L3jAtonN85

From the June issue— Founder mutations in #follicularlymphoma precursors, by @schroersmartin, Joanne Soo, @gabriel_brisou, @FSchererMD, Bertrand Nadel, @SRoulland, @max_diehn, @AshAlizadeh et al. https://t.co/GjioWYOslA @CIML_Immunology @StanfordCancer

Together, our findings suggest a model of FL where BCL2 lesions are 1st, followed by accumulation of other mutations including CREBBP leading to clinical #lymphoma. Identifying the founding events of this cancer helps us identify important targets for #FL treatment. 10/12

Now in @CD_AACR: Tracing Founder Mutations in Circulating & Tissue-resident #FollicularLymphoma Precursors by @schroersmartin Joanne Soo @gabriel_brisou @FSchererMD Bertrand Nadel @SRoulland @max_diehn @AshAlizadeh et al. @CIML_Immunology @StanfordCancer https://t.co/TEIj4kRyFB

Pleased to announce that our review of molecular monitoring in lymphoma is now open access, with @AshAlizadeh @StefanAlig @Tessoulin_B

Outstanding @MedChiefs senior resident @Navika_Shukla presenting her work at #ASH22 on specificity of MRD testing in DLBCL with the @AshAlizadeh lab!

Excited to share our new study introducing #EPICSeq out today @NatureBiotech! https://t.co/o8YY1IH1Sy

Listen in on #ASH21 talk from @mohamshah and @BCD_AACR Scientific Editor @AshAlizadeh on #ctDNA in #LDBCL classification, then check out Dr. Alizadeh's recent review on the latest in ctDNA in @BCD_AACR.

The plethora of info extracted from ctDNA continues to grow. Great talk @mohamshah using their new EPIC-Seq to infer gene expression from #ctDNA & classify DLBCL by COO. Ability to molecularly type DLBCL minimally-invasively esp. in relapsed setting is attractive. #ASH21 #lymsm

At #AACRdlbcl21 last week, @RoschewskiMD and David Kurtz discussed #personalizedmedicine and liquid biopsy approaches guiding #DLBCL treatment. Check out their latest review: https://t.co/YTwEdsYQIL